Eschenbach Andrew Von Sells 6,059 Shares of Bausch + Lomb (NYSE:BLCO) Stock

Bausch + Lomb Corporation (NYSE:BLCO) Director Eschenbach Andrew Von sold 6,059 shares of the firm’s stock in a transaction dated Friday, August 7th. The shares were sold at an average price of $16.58, for a total value of $100,458.22. Following the completion of the transaction, the director owned 63,733 shares of the company’s stock, valued at $1,056,693.14. The trade was a 8.68% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website.

Bausch + Lomb Price Performance

NYSE:BLCO opened at $16.85 on Wednesday. Bausch + Lomb Corporation has a 52-week low of $13.61 and a 52-week high of $18.92. The company has a market cap of $6.02 billion, a P/E ratio of -35.11, a P/E/G ratio of 0.55 and a beta of 0.56. The company has a debt-to-equity ratio of 0.79, a quick ratio of 1.02 and a current ratio of 1.55. The stock’s 50-day simple moving average is $16.09 and its 200 day simple moving average is $16.39.

Wall Street Analyst Weigh In

Several research analysts have weighed in on BLCO shares. Citigroup upped their price objective on Bausch + Lomb from $19.00 to $21.00 and gave the stock a “buy” rating in a research note on Wednesday, July 8th. UBS Group started coverage on shares of Bausch + Lomb in a research note on Thursday, July 30th. They issued a “buy” rating and a $21.00 target price for the company. Weiss Ratings downgraded shares of Bausch + Lomb from a “sell (d-)” rating to a “sell (e+)” rating in a report on Friday. Deutsche Bank Aktiengesellschaft set a $16.00 price target on shares of Bausch + Lomb in a research report on Thursday, April 30th. Finally, HC Wainwright increased their price target on shares of Bausch + Lomb from $20.00 to $21.00 and gave the company a “buy” rating in a research note on Monday, August 3rd. Five equities research analysts have rated the stock with a Buy rating, seven have given a Hold rating and one has issued a Sell rating to the company. According to MarketBeat.com, the stock presently has a consensus rating of “Hold” and a consensus target price of $18.75.

Institutional Trading of Bausch + Lomb

A number of hedge funds have recently made changes to their positions in BLCO. Cetera Investment Advisers increased its holdings in shares of Bausch + Lomb by 3.9% during the 4th quarter. Cetera Investment Advisers now owns 18,713 shares of the company’s stock worth $320,000 after acquiring an additional 711 shares during the last quarter. Northwestern Mutual Wealth Management Co. increased its holdings in shares of Bausch + Lomb by 38.2% in the fourth quarter. Northwestern Mutual Wealth Management Co. now owns 3,757 shares of the company’s stock valued at $64,000 after purchasing an additional 1,039 shares during the last quarter. Handelsbanken Fonder AB raised its position in shares of Bausch + Lomb by 5.3% in the second quarter. Handelsbanken Fonder AB now owns 22,000 shares of the company’s stock valued at $364,000 after purchasing an additional 1,100 shares during the period. Caitong International Asset Management Co. Ltd lifted its stake in shares of Bausch + Lomb by 104.1% during the 4th quarter. Caitong International Asset Management Co. Ltd now owns 2,227 shares of the company’s stock worth $38,000 after buying an additional 1,136 shares during the last quarter. Finally, Wells Fargo & Company MN boosted its holdings in shares of Bausch + Lomb by 31.2% during the 4th quarter. Wells Fargo & Company MN now owns 5,903 shares of the company’s stock worth $101,000 after buying an additional 1,403 shares during the period. 11.07% of the stock is owned by institutional investors and hedge funds.

About Bausch + Lomb

Bausch + Lomb Corporation operates as an eye health company in the United States, Puerto Rico, China, France, Japan, Germany, the United Kingdom, Canada, Russia, Spain, Italy, Mexico, Poland, South Korea, and internationally. It operates in three segments: Vision Care, Pharmaceuticals, and Surgical. The Vision Care segment provides contact lens that covers the spectrum of wearing modalities, including daily disposable and frequently replaced contact lenses; and contact lens care products comprising over-the-counter eye drops, eye vitamins, and mineral supplements that address various conditions, such as eye allergies, conjunctivitis, dry eye, and redness relief.